FDA approves Tretten to treat rare genetic clotting disorder

The U.S. Food and Drug Administration has approved Tretten, Coagulation Factor XIII A-Subunit , the first recombinant product for use in the routine prevention of bleeding in adults and children who have a rare clotting disorder, known as congenital Factor XIII A-subunit deficiency.

http://www.medicalnewstoday.com/releases/270613.php